Audentes Therapeutics Nets $30 Mln in Series A Financing
Audentes Therapeutics said Thursday that it has secured $30 million in Series A financing. The lead investor was OrbiMed Advisors. Versant Ventures and 5AM Ventures also participated in the round. Also, Jonathan Silverstein of OrbiMed Advisors, has been named chairman of Audentes' board. Headquartered in San Francisco, Calif., Audentes Therapeutics is a biotechnology company.
18 July 2013•3 mins read
